Choroidal Melanoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Choroidal melanoma is sporadic cancer that affects adults' eyes. It may not cause any symptoms for many years before symptoms begin. Symptoms depend on the exact location, tumor size within the eye, and if the tumor is causing secondary effects to the retina. Blurred vision, double vision (diplopia), irritation, pain, flashes of light in the eye, a reduction in the total area of invention, and loss of sight are some of the signs that can appear. The sense of a foreign body in the field of vision (floaters), redness, bulging or displacement of the eye, a change in the shape of the pupil, and pressure within the eye are all reported as additional CM symptoms. Metamorphopsia is a visual distortion in which a person's straight lines appear wavy, and parts of the grid appear blank when looking at a grid of straight lines. It may spread to other parts of the body. The liver is the most generally affected organ in the body by ocular melanoma metastasis (80% of cases), but it can also affect the lungs, skin or soft tissue, and bone. According to some estimates, 40-50 percent of people with ocular melanoma will develop metastasis.

In the United States, the rate of choroidal melanoma varies from 5 to 6.5 cases per 100,000 people. Ocular melanoma is less common than skin melanoma, accounting for only 3-4 percent of all melanoma cases.

The competitive landscape of Choroidal Melanoma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Choroidal Melanoma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Choroidal Melanoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Choroidal Melanoma – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          AU-011 Aura Biosciences           Phase 2

2          ranibizumab      Genentech, Inc. Phase 2

3          Sunitinib            Pfizer    Phase 2

4          nab-paclitaxel    Celgene Corporation     Phase 2

5          melphalan         Delcath Systems Inc.     Phase 3

6          Taxoprexin        American Regent, Inc.   Phase 2